CATALYSTSeeking Alpha • 21h ago
Profound Medical: Q3 Revenue Beats Outlook (Rating Upgrade)Seeking Alpha report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
Why PROF Stock surged +12.12% Today — RQD Quant Desk Flash
$6.57 +12.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $6.70
Profound Medical Corp. (PROF) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $240.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PROF Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PROF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Profound Medical Corp. (NASDAQ: PROF) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $6.57 (+12.12% 1D, market cap $240.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PROF ranks #463 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PROF compare to UTMD and OSUR in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), PROF carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 70.8%, and ROIC of -35.0%. By comparison, UTMD (Utah Medical Products Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC 26.9%, cap $216.7M) and OSUR (OraSure Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $271.7M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while UTMD leads on capital efficiency (26.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PROF?
▼
Per PROF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001628808), Profound Medical Corp. generated $16.1M in revenue (+65.3% YoY), -$42.6M in net income, and -$38.4M in free cash flow against $77.5M in total assets and $4.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $6.70 (+1.99%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PROF)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY PROF SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (35% of score)
Altman Z-Score 5.97 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (25% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$7.01-15.5% Next Q
48
Q2 (-2Q)Grade D$5.92-4.7% Next Q
45
Q3 (-1Q)Grade D$5.64+16.5% Next Q
43
CurrentGrade D-$6.57-7.4% Hist 90D α
40
Trajectory: D (48) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PROF Turnaround Squeeze
While PROF currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.20) and Max Pain ($6.90) forces dealer call-delta covering toward $9.40.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PROF• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PROF Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PROF Stock surged +12.12% Today — RQD Quant Desk Flash
Profound Medical Corp. (PROF) surged +12.12% to $6.57, trading at 43% of its 52-week range ($4.8 – $8.95). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 43% of its 52-week range ($4.8 – $8.95) with RSI-14 at 56.4 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $6.57 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 70.8% gross margin and $0 annual free cash flow.
Live PROF Headlines & Catalysts
CATALYSTYahoo Finance • 1d ago
Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?Yahoo Finance report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
CATALYSTInvesting.com • 1d ago
Profound Medical stock surges 20% on raised Q3 revenue outlookInvesting.com report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
CATALYSTGuruFocus • 1d ago
Profound Medical (PROF) Surges 17.1% Pre-Market Amid Broader MarGuruFocus report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Gross margin is expected to top 70% as Profound Medical (PROF) previews preliminary Q3 revenue.Stock Titan report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to TradeYahoo Finance report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
MARKET WIREChartMill • 1d ago
What's going on in today's after hours sessionChartMill report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 1d ago
Raymond James reiterates Strong Buy on Profound Medical stock, $11 targetInvesting.com report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 1d ago
3 Canadian AI Healthcare Stocks With Revenue Growth Up To 53%AI data centres are drawing huge new power infrastructure in places like Teesside, and that demand for computing muscle has a direct read across to Canadian healthcare companies building AI tools for hospitals, clinics,
MARKET WIREBenzinga • 3d ago
12 Health Care Stocks Moving In Friday's Intraday SessionGainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PROF)
- ✓Walkthrough of PROF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PROF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -1.94%📐 HORIZONTAL RANGE
2026-11-03O $5.86H $6.57L $5.86C $6.57VOL 475.5K
RES: $7.40SUP: $5.07SMA50: $6.20SMA200: $6.65
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PROF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +65.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on PROF today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PROF. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PROF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PROF)
Health Care Rank #463 of 1015
⚔️ UTMD vs PROF Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PROF vs. UTMD, OSUR, INFU, ANIK)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Profound Medical Corp. (PROF) ranks #463 by composite RQD confidence (40/100, grade D-) and #550 by equity capitalization ($240.0M). Within this direct 5-issuer industry benchmark cohort, INFU leads on earnings valuation at 43.4x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. INFU currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with PROF at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PROF
ACTIVE
Profound Medical Corp. | D- | 40/100 | — | 70.8% | -35.0% | +12.12% | $240.0M | Benchmark Subject |
| UTMD Utah Medical Products Inc. | C | 62/100 | — | 57.1% | 26.9% | +1.91% | $216.7M | /utmd-vs-prof → |
| OSUR OraSure Technologies Inc. | E | 31/100 | — | 41.9% | -35.0% | -3.43% | $271.7M | /osur-vs-prof → |
| INFU InfuSystems Holdings Inc. | B+ | 77/100 | 43.4x | 56.0% | 12.8% | -2.63% | $280.2M | /infu-vs-prof → |
| ANIK Anika Therapeutics Inc. | D+ | 53/100 | — | 56.6% | -10.2% | -3.85% | $280.4M | /anik-vs-prof → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001628808 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Profound Medical Corp. (PROF) reported GAAP revenue of $16.1M (+65.3% vs. FY2024 revenue of $9.7M , and +172.9% cumulative change since FY2023) , GAAP net income of -$42.6M, operating cash flow of -$38.2M, and free cash flow of -$38.4M (-63.7% YoY). On the balance sheet, PROF closed FY2025 with $77.5M in total assets against $4.5M in total debt (Altman Z-Score: 5.97, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $16.1M | -$42.6M | -$38.2M | -$38.4M | $77.5M | $4.5M |
| FY2024 (FY) | 2024-12-31 | $9.7M | -$27.8M | -$23.5M | -$23.5M | $70.2M | $2.9M |
| FY2023 (FY) | 2023-12-31 | $5.9M | -$28.3M | -$22.6M | -$22.6M | — | — |
3. PROF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PROF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Profound Medical Corp. (NASDAQ: PROF) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $6.57 (+12.12% 1D, market cap $240.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PROF ranks #463 in composite RQD confidence.
How does PROF compare to UTMD and OSUR in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), PROF carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 70.8%, and ROIC of -35.0%. By comparison, UTMD (Utah Medical Products Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC 26.9%, cap $216.7M) and OSUR (OraSure Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $271.7M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while UTMD leads on capital efficiency (26.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PROF?
Per PROF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001628808), Profound Medical Corp. generated $16.1M in revenue (+65.3% YoY), -$42.6M in net income, and -$38.4M in free cash flow against $77.5M in total assets and $4.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PROF trading relative to its 50-day, 200-day, and 52-week technical levels?
PROF last traded at $6.57 (+12.12% on volume of 475,528 shares), positioning the stock +5.97% above its 50-day simple moving average ($6.20) and -1.20% below its 200-day simple moving average ($6.65). Across its 52-week range of $4.80 to $8.95, PROF sits at the 42.7% percentile with a 14-day RSI of 56.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($5.75 to $7.39).
ROARABLE RATING BRIEF • RQD 40/100 (D-)
✓ SEC XBRL & RQD VERIFIED
PROF — Profound Medical Corp.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Profound Medical Corp. (PROF) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $6.57 (+12.12% 1D, market capitalization $240.0M).
- Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 70.8%, operating margin of -60.0%, and free cash flow yield of -17.93%.
- Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (6/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 5.97, Piotroski F-Score of 5/9, and Debt/Equity of 0.07x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Profound Medical Corp. (PROF) is a NASDAQ-listed issuer in the Health Care sector and Medical/Dental Instruments industry. Gross margin is reported at 70.8%, per the market data.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Profound Medical Corp. (PROF) reported $16.1M in annual revenue (up from $9.7M in FY2024, +65.3% YoY) and -$42.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.9M revenue, -$28.3M net income) through FY2025, PROF scaled operating cash flow to -$38.2M and free cash flow to -$38.4M, backed by $77.5M in total assets against $4.5M in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -17.93% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $4.80 – $8.95 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — The only sector-level context is the Health Care sector and Medical/Dental Instruments industry classification from the profile. Investors should treat any ripple analysis beyond that classification as unsupported by the provided sources.
- Key Question #1: Can PROF sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $16.1M and free cash flow of -$38.4M, how will capital allocation balance growth reinvestment against $4.5M in total debt?
- Key Question #3: How sensitive is PROF's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
PROF Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Profound Medical Corp. (PROF) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Seeking Alpha • 21h ago
Profound Medical: Q3 Revenue Beats Outlook (Rating Upgrade) Seeking Alpha report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect? Yahoo Finance report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Investing.com • 1d ago
Profound Medical stock surges 20% on raised Q3 revenue outlook Investing.com report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST GuruFocus • 1d ago
Profound Medical (PROF) Surges 17.1% Pre-Market Amid Broader Mar GuruFocus report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Gross margin is expected to top 70% as Profound Medical (PROF) previews preliminary Q3 revenue. Stock Titan report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade Yahoo Finance report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ChartMill • 1d ago
What's going on in today's after hours session ChartMill report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 1d ago
Raymond James reiterates Strong Buy on Profound Medical stock, $11 target Investing.com report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PROF Bull vs. Bear Conversation Board — What's Your Call at $6.57?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PROF 🐻 33% BEARISH CONVICTION
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH
🎯 Target: $8.02 (+22.1%)
📌 Pinned Debate Revenue grew from $5.9M in FY 2023 to $16.1M in FY 2025 while the forensic balance sheet scored 14/20 with Debt/Equity of 0.07 and cash
Picked up a starter position in PROF in my $100K Virtual Cash book at $6.57. Revenue grew from $5.9M in FY 2023 to $16.1M in FY 2025 while the forensic balance sheet scored 14/20 with Debt/Equity of 0.07 and cash of $59.7M against debt of $4.5M.. Trading inside a $4.80–$8.95 52-week range with -17.93% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.
SectorRotator 🐂 BULL
@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (70.8%) holds, EPS grows into the multiple faster than bears think.
BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH
🎯 Target: $5.39 (-18.0%)
Spot @ $6.57 Operating income fell to -$41.3M in FY 2025 with FCF of -$38.4M and FCF yield of -17.93%, while ROIC is -35% and insider conviction sco
Here is the bear case nobody on the bull side wants to address on PROF: Operating income fell to -$41.3M in FY 2025 with FCF of -$38.4M and FCF yield of -17.93%, while ROIC is -35% and insider conviction scores only 3/20.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.